Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0d4aaab7042ef967103d8c9cf7d505c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
filingDate |
2018-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b19b7e84d01a86f75cda5bcf645734d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75aa3c2d40712622323f0be0ff44b3b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23cf0d5553c083eac37184f1b206e1ec |
publicationDate |
2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20210040992-A |
titleOfInvention |
Chemokine-reactive activated natural killer cells with secondary homing activation against a validated target |
abstract |
Provided herein is a modified NK-92 cell comprising a nucleic acid encoding a C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cell further comprises a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19), or a combination thereof. Compositions and kits comprising modified NK-92 cells are also provided. It provides a method of producing a modified cell and a method of treating cancer using the cell. |
priorityDate |
2018-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |